Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05892328 · ClinicalTrials.gov registry record · NA
Watermelon Dose Response Blood Pressure Study
A NA study of Cardiovascular Diseases and Prehypertension, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- Active
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05892328: Active NA study of Cardiovascular Diseases and Prehypertension, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
NCT05892328 is a NA study of Cardiovascular Diseases and Prehypertension that is active but no longer recruiting, run by Clinical Nutrition Research Center, Illinois Institute of Technology. The registered enrollment target is 36 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05892328, a NA study of Cardiovascular Diseases and Prehypertension, is active but no longer recruiting, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
1. Primary outcome: To evaluate the dose response effects of watermelon flesh in regulating Blood Pressure (BP) in individuals with pre-hypertension. 2. Secondary outcomes: To study the dose-response effects of watermelon flesh intake on cardio-metabolic risk factors including plasma metabolic markers, lipid profile and nitrate/nitrite levels in individuals with pre-hypertension.
Primary Outcome
This objective will be accomplished by assessing the 24-h Ambulatory Blood Pressure Machine (ABPM) in individuals with pre-hypertension before and after 4 weeks of watermelon flesh intake. Two doses of watermelon flesh will be tested (1 and 2 cup servings) compared to control.
Conditions Studied
Interventions
- OTHER Control
- OTHER Watermelon Flesh Dose 1
- OTHER Watermelon Flesh Dose 2
Study Locations (1)
Illinois
- Clinical Nutrition Research Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-04-07 |
| Est. Completion | 2026-03-01 |
| Phase | NA |
What the registry record for NCT05892328 still lists
NCT05892328 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 3 interventions - of which Control is the first listed.
NCT05892328 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05892328 about?
NCT05892328 is a clinical study titled "Watermelon Dose Response Blood Pressure Study". 1. Primary outcome: To evaluate the dose response effects of watermelon flesh in regulating Blood Pressure (BP) in individuals with pre-hypertension. 2. Secondary outcomes: To study the dose-response effects of watermelon flesh intake on cardio-metabolic risk factors including plasma metabolic marke...
What is the current status of trial NCT05892328?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2023-04-07. Estimated completion is 2026-03-01.
What conditions does trial NCT05892328 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Prehypertension.
What interventions are being tested in trial NCT05892328?
The interventions under investigation include: Control (OTHER), Watermelon Flesh Dose 1 (OTHER), Watermelon Flesh Dose 2 (OTHER).
Who is sponsoring clinical trial NCT05892328?
This trial is sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05892328 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05892328's enrollment target sits among peer trials
36 255th of 300 higher than 45 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI